Submit a Comment

Genitourinary Cancers: Immediate Impact of 2016 ASCO Presentations on Clinical Practice

Introduction

In an effort to provide you with timely market feedback from the 2016 ASCO Annual Meeting, OBR and MDoutlook are pleased to share results from MDoutlook’s OncoPolls™ conducted immediately after the meeting. This report explores genitourinary (non-prostate) presentations concerning the use of checkpoint inhibitors as therapy for bladder cancer and new overall survival data for agents in kidney cancer.

OncoPoll™ Methodology

  • Primary research phase involved a global survey to verified and validated medical oncologists and multi-disciplinary physicians with an identified clinical interest in genitourinary cancers utilizing targeting parameters within the proprietary MDoutlook® global cancer treater panel
  • Timing: June 2016. Launched 4 days after close of 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, June 3-7, 2016
  • Fielding to proprietary panel of cancer treaters, targeted by clinical interest
  • Data capture via interactive web-based survey instrument, utilizing proven MDoutlook methodology and proprietary technology
  • Links to discussed abstracts on the ASCO website were provided within the survey
  • Reponses at data collection: 89
  • Responses are from 20 countries: Argentina, Austria, Belgium, Brazil, Canada, Chile, France, Germany, Israel, Italy, Netherlands, Norway, Pakistan, Poland, South Africa, Spain, Sweden, Turkey, United Kingdom and US

OncoPoll_GU_Figure1

OncoPoll_GU_Figure2

OncoPoll_GU_Figure3

Key Conclusions

  • On a 0 – 5 scale of 0 = no awareness to 5 = very aware, clinicians have an above average awareness of these presentations
    • A general higher level of awareness is seen by those in the US (~0.5-0.7 higher ratings)
    • The awareness about durvalumab was somewhat lacking compared to the other antibodies
  • Clinical impact, also rated on a 0 – 5 scale of 0 = no impact at all to 5 = very important, for these agents in general are seen as very clinically meaningful
    • US oncologists assign a higher importance to these agents than those outside of the US
    • In total, a slightly higher level of importance is seen for 2nd+ line than in 1st line
    • Both awareness and assigned importance is greater for those who attended the meeting than those who did not (not shown)
  • In a follow-up question, we asked if participants had used atezolizumab for urinary cancer in their practices yet (outside of clinical trials); 40% of US respondents say they had, compared to 11% of those outside of the US

OncoPoll_GU_Figure4

OncoPoll_GU_Figure5

Key Conclusions

  • On the same 0 – 5 scale, there is an above average level awareness about these presentations in the US, while awareness outside of the US is about average
    • No meaningful differences in awareness between these two abstracts
    • Much higher level of awareness among the attendees (3.8-3.9) compared to those who did not attend (2.7-2.8)
  • US oncologists view both of these presentations as very clinically important. Those outside of the US view these as less important and the nivolumab data as more important than the Meteor data
    • More importance (over a full point difference) was assigned to both presentations by the attendees than with the non-attendees (not shown)

Conclusions: Immediate Impact of 2016 ASCO Presentations on Clinical Practice for Bladder and Kidney Cancer

  • All of these studies highlight the importance of the ASCO Annual Meeting to the entire global oncology community – awareness of these presentations are high and can occur quite quickly even for those who did not attend
  • The importance of these presentations suggest that integration of these results into clinical practice will happen in relatively short order, especially since most of these agents are already widely available and in use

For a more detailed analysis report, please click here to download the full report.

Submitted by Robert Stephan, VP, Research and Physician Society, and Jan Heybroek, President MDoutlook.

You must be logged in to post a comment